Methylphenidate Viatris Limited

Methylphenidate, the active ingredient in Methylphenidate Viatris Limited, is a central nervous system stimulant presented as an oral dosage form for oral use. It is prescribed for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults. GNH USA supplies Methylphenidate Viatris Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate acts on central nervous system pathways involved in attention and wakefulness. - Attention deficit hyperactivity disorder (children): improves focus, reduces hyperactivity and impulsivity. - Attention deficit hyperactivity disorder (adults): lessens inattention and improves executive function. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or vomiting.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychosis: hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or breathing difficulty.

Before initiating therapy, clinicians should evaluate several safety aspects. - Cardiovascular assessment: review blood pressure and heart rate. - Growth monitoring: track height and weight in pediatric patients. - Drug interaction review: avoid concurrent MAO inhibitor use. - Psychiatric history: assess for anxiety, tics, or bipolar disorder. - Store at room temperature: keep in the original container, protect from moisture.

Methylphenidate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: potential reduction of blood‑pressure control.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate levels. - Selective serotonin reuptake inhibitors (SSRIs): monitor for increased nervous system stimulation. - Antihistamines: possible additive insomnia or agitation.